<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has completed a placing of 5,085,000 new H shares under its general mandate, raising gross proceeds of about HK$290 million at HK$57.03 per share from at least six professional and institutional investors who remain below the substantial shareholder threshold. The new shares represent roughly 1.65% of the enlarged H share capital and 1.26% of total issued shares, modestly diluting existing holders while broadening the investor base. Net proceeds of approximately HK$282.15 million will be directed mainly to research and development, with about 57% earmarked for advancing clinical programs for its core oncology drug Tinengotinib across multiple cancer indications and for TT-00973. Around 33% of the funds will support manufacturing and commercialization of Tinengotinib in China, including building commercial teams and marketing, while the remaining 10% is allocated to working capital and general corporate purposes, strengthening TransThera’s funding for near- to mid-term growth initiatives. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a biopharmaceutical company based in the People’s Republic of China, focused on developing and commercializing innovative oncology therapies. Its core product, Tinengotinib, targets multiple cancer indications, and the company is also advancing pipeline candidates such as TT-00973 for further clinical development and potential market expansion. Average Trading Volume: 2,482,081 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$21.35B Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page.</div>

02617

513120

520880

159506

159992

520500

159892

520690

159316

159570

TransThera Sciences (Nanjing), Inc. has raised approximately HK$282 million through the placement of 5,085,000 new H shares at HK$57.03 each. The funds will primarily support research and development, with 57% allocated to advancing its oncology drug Tinengotinib, 33% for manufacturing and commercialization in China, and 10% for working capital. This move aims to broaden the investor base while modestly diluting existing shareholders. TransThera focuses on innovative oncology therapies and is also developing pipeline candidates like TT-00973.

Tip Ranks

TRANSTHERA-B

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

TransThera Raises HK$282 Million via H-Share Placing to Fund Cancer Drug Push